The achondroplasia treatment market consists of drugs used in the treatment of achondroplasia which is the most common form of dwarfism. Drugs in this market relieve pain, improve respiratory function and mobility. Achondroplasia is caused by a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene and presents as disproportionate short stature.
The global achondroplasia treatment market is estimated to be valued at US$127.8 Mn in 2023 and is expected to exhibit a CAGR of ... Read more
